Sanofi takes its own drug pric­ing pledge, point­ing to a de­cline in their ag­gre­gate net price

Sanofi CEO Sanofi Olivi­er Brandi­court (left), flanked by CFO Jerome Con­t­a­mine, speaks dur­ing the pre­sen­ta­tion of the group’s 2016 re­sults in Paris on Feb­ru­ary 8, 2017. ER­IC PIER­MONT/AFP/Get­ty

What do you do when your in­dus­try is rou­tine­ly pil­lo­ried by the pres­i­dent of the US for be­ing run by a group of white col­lar price gougers, rou­tine­ly rip­ping off the Amer­i­can con­sumer?

In Big Phar­ma’s case, you be­gin to un­der­stand that those opaque drug prices you work with are a big part of the prob­lem, and you start to shed a light on the pric­ing menu, while com­mit­ting to an eth­i­cal ap­proach on pric­ing that might help cool the white-hot rhetoric.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.